A modified immunotherapy regimen for advanced melanoma showed a 49% response rate and extended median overall survival to 42 ...

As the number of patients with multiple myeloma and lymphoma treated with CAR-T therapy increases, health systems are ...

Schizophrenia spectrum disorders significantly increase cardiovascular and metabolic disease risks, partly due to antipsychotic-induced weight gain and glucose dysregulation.

The use of an older medication at the time of surgery can reduce the need for red blood cell transfusions, according to a ...

Strong positive results of a novel combination of two immunotherapy drugs as a treatment for multiple myeloma after other treatments have failed suggest the combination could be a “functional cure,” ...

Jaypirca (pirtobrutinib) improved progression-free survival in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) when compared with bendamustine ...

According to a report written by sister publication Dermatology Times (DT) in November, research from the 2025 Inflammatory Skin Disease Summit noted that itch can signal inflammation in the body.

Chimeric antigen receptor (CAR) T-cell therapy can cure certain types of blood cancer, but cost and a general lack of ...

In this interview, George Eastwood, executive director of the Emily Whitehead Foundation and CAR T Vision steering committee member discusses barriers and strategies for expanding access to CAR T-cell ...

Robert Orlowski, M.D., Ph.D., of the MD Anderson Cancer Center shared early results from the LINKER-MM1 trial with Managed Healthcare Executive, which is testing linvoseltamab in people newly ...

He also discussed how linvoseltamab could fit into care for newly diagnosed patients. With several treatment options already available, he said linvoseltamab may become another strong choice, ...

Researchers said future studies could help refine the use of Jaypirca alone or in combination with other therapies as a frontline treatment. She added that they are also continuing to investigate ...